Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (GIPI)

Clinical Trial ID NCT01363206

Rank	Title	Journal	Year	PubWeight™‹?›
1	Improved survival with ipilimumab in patients with metastatic melanoma.	N Engl J Med	2010	67.34
2	Improved endpoints for cancer immunotherapy trials.	J Natl Cancer Inst	2010	5.23
3	Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.	J Clin Oncol	2000	2.37
4	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.	J Leukoc Biol	2013	1.90
5	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.	Blood	2008	1.81
6	CTLA-4 blockade in tumor models: an overview of preclinical and translational research.	Cancer Immun	2013	1.71
7	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy.	Biomed Res Int	2015	1.25
8	Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.	Cancer J	2012	0.97
9	Checkpoint modulation in melanoma: an update on ipilimumab and future directions.	Curr Oncol Rep	2013	0.94
10	Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".	Toxins (Basel)	2014	0.92
11	GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.	Oncoimmunology	2015	0.80